Ruolan Han, Ph.D.
Affiliations: | 2007 | University of Rochester, Rochester, NY |
Area:
Glial development, multiple sclerosis, brain tumoursGoogle:
"Ruolan Han"Mean distance: 17.2 (cluster 32) | S | N | B | C | P |
Parents
Sign in to add mentor| Mark Noble | grad student | 2007 | Rochester | |
| (The central nervous system toxicity of metabolic chemotherapy.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Youssef Y, Karkhanis V, Chan WK, et al. (2020) Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma. Haematologica |
| Nomura M, Rainusso N, Lee YC, et al. (2019) Tegavivint and the β-catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. Journal of the National Cancer Institute |
| Bailey C, Romero M, Han R, et al. (2018) IMMU-19. LSD1 MODULATES NK CELL IMMUNOTHERAPY THROUGH AN ONCO-IMMUNOGENIC GENE SIGNATURE IN DIPG Neuro-Oncology. 20: i102-i102 |
| Han R, Huang S, Bao Y, et al. (2016) Upregulation of SOX4 antagonizes cellular senescence in esophageal squamous cell carcinoma. Oncology Letters. 12: 1367-1372 |
| Zhao JK, Wu M, Kim CH, et al. (2016) Jiangsu Four Cancers Study: a large case-control study of lung, liver, stomach, and esophageal cancers in Jiangsu Province, China. European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (Ecp) |
| Li L, Wang Y, Peng T, et al. (2016) Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway. Oncotarget |
| Shang Z, Li Y, Hsu I, et al. (2016) Targeting estrogen/estrogen receptor alpha will enhance Bacillus Calmette-Guerin efficacy in bladder cancer. Oncotarget |
| Yeo SY, Itahana Y, Guo AK, et al. (2016) Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation. Elife. 5 |
| Shang Z, Li Y, Zhang M, et al. (2015) Anti-androgen therapy with Hydroxyflutamide or androgen receptor degradation enhancer ASC-J9® enhances BCG efficacy to better suppress bladder cancer progression. Molecular Cancer Therapeutics |
| Sun E, Zhang W, Wang L, et al. (2015) Down-regulation of Sphk2 suppresses bladder cancer progression. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine |